TP53 and ovarian cancer: However, many cases of high-grade ovarian serous carcinoma, the most common subtype of ovarian cancer, mostly bearing the various mutations in the TP53 gene, relapse within 6 months after the first-line therapy due to chemoresistance, with a median overall survival of less than a year [5, 6].